GSK, mRNA
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is targeted for patients with lung cancer,
Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA ...
A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...
Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...
Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...
Frustrated when Brazil could not get COVID vaccines, two Brazilian doctors (who have been best friends since college) decided ...
Did you know that the COVID-19 mRNA vaccination is safe and beneficial for children and adults with sickle cell disease?
With a trading volume of 1,014,812, the price of MRNA is up by 0.33%, reaching $76.86. Current RSI values indicate that the ...
In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Moderna (MRNA – Research Report), with a price ...
Results from the first-in-human trial of a new mRNA-based cancer vaccine are promising, as are early results from two other ...
Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback